#iganephropathy — Public Fediverse posts

https://www.europesays.com/ch/104626/ Novartis (SWX:NOVN) Wins Full FDA Nod For Fabhalta And Wider EU Itvisma Use #AcceleratedApproval #FDAApproval #GeneTherapy #IgANephropathy #InvestmentDecisions #KidneyDisease #KidneyFunction #Novartis #RareDisease #RegulatoryDecisions #SpinalMuscularAtrophy

Novartis (SWX:NOVN) Wins Full FDA Nod For Fabhalta And Wider EU Itvisma Use

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Novartis…
#Europe #EU #acceleratedapproval #EuropeanUnion #FDAapproval #genetherapy #IgAnephropathy #investmentdecisions #kidneydisease #kidneyfunction #Novartis #raredisease #regulatorydecisions #spinalmuscularatrophy
https://www.europesays.com/europe/96524/

Should Viatris’ Japan IgA Nephropathy Win and New Loan Shape VTRS Investors’ Next Move?

Viatris Inc. recently reported positive Phase 3 results in Japan for VR-205 (Nefecon), an IgA nephropathy treatment, and…
#EuropeSays #Japan #JP #IgAnephropathy #MizuhoBank #Viatris
https://www.europesays.com/japan/53838/

AstraZeneca (LSE:AZN) Forms Five Year YMCA Cancer Partnership As Ultomiris Wins Priority Review

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. AstraZeneca…
#EuropeSays #Britain #Europe #EU #AstraZeneca #IgAnephropathy #nationalpartnership #Priority #YMCAoftheUSA
https://www.europesays.com/britain/71012/

https://www.europesays.com/britain/71012/ AstraZeneca (LSE:AZN) Forms Five Year YMCA Cancer Partnership As Ultomiris Wins Priority Review #AstraZeneca #IgANephropathy #NationalPartnership #Priority #YMCAOfTheUSA

https://www.europesays.com/ch/78112/ Novartis reports positive results from Phase III ALIGN trial for IgAN #decline #DoubleBlindTrial #EuropeanRenalAssociation #IgANephropathy #IgAN #KidneyFunction #Novartis #placebo

https://www.europesays.com/ch/77916/ Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years #ChangeFromBaseline #EuropeanRenalAssociation #IgANephropathy #KidneyFunction #KidneyTransplantation #Novartis #patients #ProteinInTheUrine #ReceptorAntagonist

https://www.europesays.com/ch/77526/ Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years #ChangeFromBaseline #EuropeanRenalAssociation #IgANephropathy #KidneyFunction #KidneyTransplantation #Novartis #patients #ProteinInTheUrine #ReceptorAntagonist

https://www.europesays.com/ch/77514/ Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years #ChangeFromBaseline #EuropeanRenalAssociation #IgANephropathy #KidneyFunction #KidneyTransplantation #Novartis #patients #ProteinInTheUrine #ReceptorAntagonist

https://www.europesays.com/ch/76635/ New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength #DataIntegration #DataPrivacy #EuropeanRenalAssociation #IgANephropathy #KidneyCare #KidneyDiseases #KidneyFunction #Novartis #OralPresentation #patients

https://www.europesays.com/ch/72749/ New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength #DataIntegration #DataPrivacy #EuropeanRenalAssociation #IgANephropathy #KidneyCare #KidneyDiseases #KidneyFunction #Novartis #OralPresentation #patients

https://www.europesays.com/ch/71911/ New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength #DataIntegration #DataPrivacy #EuropeanRenalAssociation #IgANephropathy #KidneyCare #KidneyDiseases #KidneyFunction #Novartis #OralPresentation #patients

https://www.europesays.com/ch/45548/ Novartis Fabhalta Data Sharpens IgA Nephropathy Outlook And Valuation Case #IgANephropathy #Novartis #PharmaceuticalPortfolio #StockPortfolio #TreatmentOptions

https://www.europesays.com/ch/?p=43197 Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% #DiseaseProgression #IgANephropathy #KidneyDamage #KidneyFailure #KidneyFunction #Novartis

https://www.europesays.com/ch/40771/ Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% #DiseaseProgression #IgANephropathy #KidneyDamage #KidneyFailure #KidneyFunction #Novartis

https://www.europesays.com/ie/168996/ Pediatric patients with primary glomerular diseases may experience faster kidney function decline #biopsy #children #Éire #Glomerulosclerosis #Health #IE #IgANephropathy #Ireland #Kidney #KidneyFailure #Nephrology #Nephropathy #Research

Budesonide for IgA-Nephropathy, Phase 3

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01554-4/fulltext?rss=yes

Does the company have the guts to do a head-to-head-trial against regular budesonide?

#nephrology #IgANephropathy

Budesonide for IgA-Nephropathy, Phase 3

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01554-4/fulltext?rss=yes

Does the company have the guts to do a head-to-head-trial against regular budesonide?

#nephrology #IgANephropathy

Budesonide for IgA-Nephropathy, Phase 3

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01554-4/fulltext?rss=yes

Does the company have the guts to do a head-to-head-trial against regular budesonide?

#nephrology #IgANephropathy

This is the methods section of interest - RASi ‘optimized’ ie the maximum tolerated dose had to be at least 50% of max (😏) and BP < 150/100

Note biopsy timing doesn’t matter

Note exclusion for heart failure (Endothelin antagonist specific issue!)

This is the interim result for FDA approval (obtained) of 36 week follow up, final follow up is 114 weeks, plus an observational period

#Sparsentan #IgANephropathy

2/

Headline result from the #Sparsentan PROTECT trial in #IgANephropathy in #Lancet https://authors.elsevier.com/c/1grIl_3CjG8WAP

1/🧵

Full text link via @Rheault_m

Big proteinuria reduction:

This is the methods section of interest - RASi ‘optimized’ ie the maximum tolerated dose had to be at least 50% of max (😏) and BP < 150/100

Note biopsy timing doesn’t matter

Note exclusion for heart failure (Endothelin antagonist specific issue!)

This is the interim result for FDA approval (obtained) of 36 week follow up, final follow up is 114 weeks, plus an observational period

#Sparsentan #IgANephropathy

2/

Headline result from the #Sparsentan PROTECT trial in #IgANephropathy in #Lancet https://authors.elsevier.com/c/1grIl_3CjG8WAP

1/🧵

Full text link via @Rheault_m

Big proteinuria reduction:

This is the methods section of interest - RASi ‘optimized’ ie the maximum tolerated dose had to be at least 50% of max (😏) and BP < 150/100

Note biopsy timing doesn’t matter

Note exclusion for heart failure (Endothelin antagonist specific issue!)

This is the interim result for FDA approval (obtained) of 36 week follow up, final follow up is 114 weeks, plus an observational period

#Sparsentan #IgANephropathy

2/

Headline result from the #Sparsentan PROTECT trial in #IgANephropathy in #Lancet https://authors.elsevier.com/c/1grIl_3CjG8WAP

1/🧵

Full text link via @Rheault_m

Big proteinuria reduction:

This is the methods section of interest - RASi ‘optimized’ ie the maximum tolerated dose had to be at least 50% of max (😏) and BP < 150/100

Note biopsy timing doesn’t matter

Note exclusion for heart failure (Endothelin antagonist specific issue!)

This is the interim result for FDA approval (obtained) of 36 week follow up, final follow up is 114 weeks, plus an observational period

#Sparsentan #IgANephropathy

2/

Headline result from the #Sparsentan PROTECT trial in #IgANephropathy in #Lancet https://authors.elsevier.com/c/1grIl_3CjG8WAP

1/🧵

Full text link via @Rheault_m

Big proteinuria reduction:

This is the methods section of interest - RASi ‘optimized’ ie the maximum tolerated dose had to be at least 50% of max (😏) and BP < 150/100

Note biopsy timing doesn’t matter

Note exclusion for heart failure (Endothelin antagonist specific issue!)

This is the interim result for FDA approval (obtained) of 36 week follow up, final follow up is 114 weeks, plus an observational period

#Sparsentan #IgANephropathy

2/

Headline result from the #Sparsentan PROTECT trial in #IgANephropathy in #Lancet https://authors.elsevier.com/c/1grIl_3CjG8WAP

1/🧵

Full text link via @Rheault_m

Big proteinuria reduction:

The rationale and design of the APPLAUSE IgAN trial of #iptacopan - a complement inhibitor - in #IgANephropathy - funded by its maker Novartis

Well timed for #NephMadness #IgANephropathy region! With a great #VisualAbstract from @edgarvlermamd

https://www.sciencedirect.com/science/article/pii/S2468024923000505

The rationale and design of the APPLAUSE IgAN trial of #iptacopan - a complement inhibitor - in #IgANephropathy - funded by its maker Novartis

Well timed for #NephMadness #IgANephropathy region! With a great #VisualAbstract from @edgarvlermamd

https://www.sciencedirect.com/science/article/pii/S2468024923000505

The rationale and design of the APPLAUSE IgAN trial of #iptacopan - a complement inhibitor - in #IgANephropathy - funded by its maker Novartis

Well timed for #NephMadness #IgANephropathy region! With a great #VisualAbstract from @edgarvlermamd

https://www.sciencedirect.com/science/article/pii/S2468024923000505

The rationale and design of the APPLAUSE IgAN trial of #iptacopan - a complement inhibitor - in #IgANephropathy - funded by its maker Novartis

Well timed for #NephMadness #IgANephropathy region! With a great #VisualAbstract from @edgarvlermamd

https://www.sciencedirect.com/science/article/pii/S2468024923000505

The rationale and design of the APPLAUSE IgAN trial of #iptacopan - a complement inhibitor - in #IgANephropathy - funded by its maker Novartis

Well timed for #NephMadness #IgANephropathy region! With a great #VisualAbstract from @edgarvlermamd

https://www.sciencedirect.com/science/article/pii/S2468024923000505

Tonight and tomorrow on #NephJC we discuss the NEFIGARD trial of #Nefecon (a targeted release #budesonide) in #IgANephropathy - supposedly with no systemic steroid exposure - but read the summary and decide for yourself http://www.nephjc.com/news/nefigard-trial

#nephrology #glomerulonephritis

#VisualAbstract from @Priti899

For a snapshot of all the trials so far, see this table made by Divya Bajpai

#iGANephropathy #NephJC

Tonight and tomorrow on #NephJC we discuss the NEFIGARD trial of #Nefecon (a targeted release #budesonide) in #IgANephropathy - supposedly with no systemic steroid exposure - but read the summary and decide for yourself http://www.nephjc.com/news/nefigard-trial

#nephrology #glomerulonephritis

#VisualAbstract from @Priti899

For a snapshot of all the trials so far, see this table made by Divya Bajpai

#iGANephropathy #NephJC

For a snapshot of all the trials so far, see this table made by Divya Bajpai

#iGANephropathy #NephJC

Tonight and tomorrow on #NephJC we discuss the NEFIGARD trial of #Nefecon (a targeted release #budesonide) in #IgANephropathy - supposedly with no systemic steroid exposure - but read the summary and decide for yourself http://www.nephjc.com/news/nefigard-trial

#nephrology #glomerulonephritis

#VisualAbstract from @Priti899

Tonight and tomorrow on #NephJC we discuss the NEFIGARD trial of #Nefecon (a targeted release #budesonide) in #IgANephropathy - supposedly with no systemic steroid exposure - but read the summary and decide for yourself http://www.nephjc.com/news/nefigard-trial

#nephrology #glomerulonephritis

#VisualAbstract from @Priti899

For a snapshot of all the trials so far, see this table made by Divya Bajpai

#iGANephropathy #NephJC